New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

@article{Leucht2003NewGA,
  title={New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis},
  author={Stefan Leucht and Kristian Wahlbeck and Johannes Hamann and Werner Kissling},
  journal={The Lancet},
  year={2003},
  volume={361},
  pages={1581-1589}
}
Are Second Generation Antipsychotics a Distinct Class?
TLDR
Although data are very limited, mid- and low-potency first-generation antipsychotics show efficacy and extrapyramidal side effects that are comparable to those of second- Generation antipsychotic medication.
Atypical Antipsychotics as First-Line Treatments for Schizophrenia
TLDR
Current guidelines recommend the use of atypical antipsychotics as first-line treatments in a wide range of patients with schizophrenia, despite significant caveats regarding the quality of evidence to support use of these drugs in general.
A review of atypical antipsychotic drugs versus conventional medication in schizophrenia
TLDR
Differences in clinical effectiveness and tolerability between conventional and atypical antipsychotic agents are described and some of the more significant adverse effects including tardive dyskinesia, weight gain, diabetes and sudden death are discussed.
Drug treatments for schizophrenia: pragmatism in trial design shows lack of progress in drug design
  • F. Cheng, P. Jones
  • Medicine, Psychology
    Epidemiology and Psychiatric Sciences
  • 2013
TLDR
Overall, large pragmatic trials of clinical effectiveness indicate that the care used in prescribing and managing drug treatments to ensure tolerability may be more important than the class of drug used.
Comparison of polypharmacy using low-dose second-generation antipsychotics plus low-dose first-generation antipsychotics with monotherapy using therapeutic-dose second-generation antipsychotics in schizophrenia – a pooled analysis
TLDR
A pooled analysis from three published 6-week, fixed dose, randomized, double-blind trials was conducted to explore whether polypharmacy using low-dose SGAs plus low- dose FGAs had efficacy and safety comparable with monotherapy using therapeutic-dose SGA in the acute treatment of 270 schizophrenia patients.
Cost-effectiveness of atypical antipsychotic medications versus conventional medication
TLDR
Long-term randomised, prospective cost-effectiveness studies that compared an atypical to a typical antipsychotic have been reviewed and it seems that, to the extent that studies mimic real world conditions, they fail to support the cost- effectiveness of the atypICAL antipsychotics.
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
TLDR
Olanzapine was the most effective in terms of the rates of discontinuation, and the efficacy of the conventional antipsychotic agent perphenazine appeared similar to that of quetiapine, risperidone, and ziprasidone.
Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia.
TLDR
Treatment with perphenazine was less costly than treatment with second-generation antipsychotics with no significant differences in measures of effectiveness, but the trial was limited by a high dropout rate, and longer-term neurological and metabolic side effects require further study.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 56 REFERENCES
Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis
TLDR
There is no clear evidence that atypical antipsychotics are more effective or are better tolerated than conventional antipsychotic drugs.
Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials.
TLDR
Overall, the currently available data suggest that new-generation antipsychotic drugs have the potential to reduce relapse rates.
Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
TLDR
These results cast some doubt on the notion that combined 5-HT(2)/D(2) antagonism is the reason that the newer antipsychotic medications are effective for negative symptoms and have fewer extrapyramidal side effects.
Review: new generation antipsychotics do not induce fewer extrapyramidal side effects than low potency antipsychotics
TLDR
Clozapine induces fewer extrapyramidal side effects than chlorpromazine in patients with schizophrenia, and more frequent in those treated with risperidone compared with methotrimeprazine.
The Risks and Benefits of Clozapine versus Chlorpromazine
TLDR
It is suggested that clozapine is well tolerated and may be therapeutically superior to chlorpromazine in treating psychotic behavior and agranulocytosis potential can be minimized by frequent white blood cell counts and removing nonresponding patients from treatment prior to the peak risk period.
The efficacy of zotepine in schizophrenia: A meta-analysis of BPRS and improvement scale scores
TLDR
Meta-analysis of the placebo-controlled trials showed that zotepine is at least as effective against all psychopathological symptoms of schizophrenia as conventional antipsychotics.
The efficacy and safety of clozapine versus chlorpromazine in geriatric schizophrenia.
TLDR
Both clozapine and chlorpromazine are effective treatments for psychosis and behavioral disturbances in geriatric schizophrenia in this population of elderly inpatients with chronic schizophrenia.
Remoxipride. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in schizophrenia.
TLDR
Clinical data show that remoxipride has antipsychotic acticvity in patients with chronic schizophrenia, and acute exacerbation of Chronic schizophrenia, with activity on both positive and negative symptoms, and it appears to offer an important tolerability advantage over haloperidol.
Risperidone versus typical antipsychotic medication for schizophrenia.
TLDR
Risperidone appears to have little or no additional effect on the positive and negative symptoms of schizophrenia but did have less tendency to cause movement disorders, largely in comparison with haloperidol.
Antipsychotic drugs: is more worse? A meta-analysis of the published randomized control trials.
TLDR
No incremental clinical improvement was found at doses above 375 mg equivalent of chlorpromazine, while a significant increase in adverse reactions was observed.
...
1
2
3
4
5
...